Mild Cognitive Impairment (MCI) Market Report and Forecast 2024-2032

Mild Cognitive Impairment (MCI) Market Overview

Mild cognitive impairment (CMI) is a neurological disorder in which a patient suffers from poor memory. It is considered a milder initial stage of Alzheimer's disease in which cognitive abilities gradually decline. In this condition, memory problems could be mild and hardly noticeable to individuals, and writing reminders and taking notes may allow a person to compensate for memory difficulties.

Mild Cognitive Impairment (MCI) Market Growth Drivers

FDA Approvals Contributing to Increased Treatment Options and Cost Efficiency

The market is experiencing significant advancements in treatment options, driven by increasing research and approvals. Mild cognitive impairment requires innovative therapies, creating a gap in effective treatment options. However, ongoing developments are expected to fill this gap. For instance, in July 2024, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion). It is intended for adult patients with early symptomatic Alzheimer's disease (AD). It includes individuals with mild cognitive impairment (MCI) as well as those in the early dementia stage of Alzheimer's disease, with confirmed amyloid pathology. Kisunla, administered once a month, is the first and only amyloid plaque-targeting therapy that provides evidence supporting the discontinuation of treatment once amyloid plaques have been cleared. The approval is poised to expand treatment possibilities and drive market growth by offering a novel, cost-effective therapy.

Rising Availability of Treatments to Meet Increasing Mild Cognitive Impairment (MCI) Market Demand

The launch of new treatments in emerging markets is a significant factor driving market growth. For instance, in June 2024, Eisai Co., Ltd. and Biogen Inc., announced that the humanised anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” has been launched in China. LEQEMBI received approval in January 2024 as a treatment for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia. China is the third country to launch LEQEMBI following the United States and Japan. The expansion of LEQEMBI to China is expected to fill the unmet need for effective MCI therapies in a rapidly ageing population, driving market growth.

Mild Cognitive Impairment (MCI) Market Trends

Mild Cognitive Impairment (MCI) Market Segmentation

Market Breakup by End User

• Hospitals
• Specialty Clinics
• Homecare Settings
• Others

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
• Japan
• India

Mild Cognitive Impairment (MCI) Market Share

Amnestic MCI Leads the Market Share by Type

Based on type, the Amnestic MCI segment dominates the market share due to its association with memory loss, a primary concern for many patients and healthcare providers. This form of MCI is more commonly identified and treated, leading to higher demand for diagnostic tools and therapies. The prevalence of memory-related symptoms makes Amnestic MCI a focal point in both research and clinical practice.

Mild Cognitive Impairment (MCI) Market Analysis by Region

The United States leads the market due to the rising incidence of geriatric population. The risk of cognitive decline is rising due to the growing ageing population as older individuals are more susceptible to the condition. The presence of a robust healthcare infrastructure and system that is well-funded by the governments and key players stimulates market growth. Heavy investments in research and development activities to explore potent drug candidates, and effective treatment modalities to treat neurodegenerative disease collectively boost market development, augmenting the leading position of the regional market. The availability of top-notch healthcare technologies in the region facilitates the integration of advanced diagnostic tools like AI-based cognitive tests, wearable devices, and neuroimaging technologies.

Additionally, the existence of a highly supportive regulatory environment, with agencies like the United States FDA and their accelerating approval processes for new drugs and therapies targeting the condition, propels regional market growth. Increasing awareness among people about the condition and health initiatives focused on early detection of cognitive decline further bolster the market.

Leading Players in the Mild Cognitive Impairment (MCI) Market

The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Pfizer Inc.

Pfizer Inc., a leading research-based pharmaceutical and biomedical company, is involved in research and development activities to create drugs for cardiovascular diseases. Pfizer plays an important role in neurological research, focusing on Alzheimer’s and mild cognitive impairment.

F.Hoffman-La Roche Ltd

Also known as Roche, it is a Swiss healthcare company focused on developing pharmaceuticals and diagnostics fo...

Novartis Pharmaceuticals Corporation

Based in Switzerland, the company is a global leader in pharmaceuticals and biotechnology. It focuses on innov...

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals was founded in 1978. It is a multinational company specialising in generic and branded p...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other key players in the market include Eisai Co., Ltd., Sun Pharmaceuticals, Teva Pharmaceuticals, and AstraZeneca.

Key Questions Answered in the Mild Cognitive Impairment (MCI) Market

• What was the mild cognitive impairment (MCI) market value in 2023?
• What is the mild cognitive impairment (MCI) market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on treatment type?
• How is the market segmented based on the indication?
• What is market segmentation based on type?
• How does segmentation by route of administration influence market dynamics?
• What are the key market segments based on age group?
• Who are the end-users in the market?
• What are the major factors aiding the mild cognitive impairment (MCI) market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• What are the major mild cognitive impairment (MCI) market trends?
• Which type is expected to dominate the market?
• Which age group will lead the market segment?
• Which treatment type will dominate the market share?
• Which route of administration will lead the market segment?
• Which end-user will lead the market?
• Who are the key players involved in the mild cognitive impairment (MCI) market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?